Short biography:

Dr. Doaa A. Ghareeb is a professor of clinical biochemistry at the Faculty of Science, Alexandria University, and the former Acting Dean of the Pharmaceutical and Fermentation Industries Development Centre at the City of Scientific Research and Technological Applications (SRAT-City). She also serves as the Director of the Biological Screening and Preclinical Trial Lab and is the co-founder and director of the Drug Preclinical Studies Center of Excellence. Dr. Ghareeb is a member of Egypt’s National Committee of Women in Science (ASRT) and a founding member of the Egyptian Association for Cancer Research. She has been actively involved in academic and scientific development since her appointment as a demonstrator in 1999. She earned her MSc in Clinical Biochemistry (2003) and her Ph.D. in Medical Biotechnology (2007) from Alexandria University. She has held key roles in faculty quality assurance, social services, and environmental development. Dr. Ghareeb’s expertise includes animal models design, protein purification, molecular biology, microbiology, immunotherapy, and clinical laboratory techniques. Her research focuses on drug design for HCV, HCC, Alzheimer’s disease, male infertility, and insulin resistance-related disorders, utilizing natural products to investigate molecular mechanisms. She has more than 160 peer-reviewed articles, and presented them in more than 120 conferences globally. She has also contributed to 26 national and international research projects. Her h-index is 25, reflecting her impactful research. Dr. Ghareeb is a recipient of several national and international scientific awards and serves on editorial boards of journals like Chemico-Biological Interactions. Her contributions span research, teaching, and technology transfer to advance the fields of biotechnology and drug development.

Field of Interest:

• Animal models design,
• Protein purification,
• Molecular medicine
• Medical biotechnology
• Cancer immunotherapy,
• Clinical laboratory techniques
• ADME study
• Drug design
• Bio-screening of natural products and small molecules.
• Nanomedicine

Short biography:

Prof. Hatem A. Abdel-Aziz is a preeminent figure in pharmaceutical organic chemistry, consistently ranked among the top 2% of scientists worldwide by Stanford University (2020–2024). With an impressive scholarly output of 270+ publications and 6825 citations (Scopus), he holds one of the highest Hirsch indices (h-index 51) at Egypt’s National Research Centre (NRC), placing him in the top 3% of researchers nationally. His pioneering work includes five international patents advancing synthetic organic chemistry methodologies in addition to six book chapters. As Principal or Co-Investigator, he has led eleven funded projects spanning bioactive heterocycle design, green chemistry applications such as microwave-assisted synthesis techniques. Renowned for global collaboration, Prof. Abdel-Aziz has partnered with institutions in the USA, Italy, Germany, Japan, and Australia. He cultivated pedagogical excellence as an Associate Professor at King Saud University (2009–2015), lecturing pharmaceutical organic chemistry courses. In 2024, he joined Pharos University in Alexandria as Professor of Pharmaceutical Organic Chemistry, contributing to Egypt’s academic leadership in drug discovery. His career epitomizes the synergy of groundbreaking research, international cooperation, and academic mentorship in advancing applied organic chemistry.

Short biography:

Wagdy Eldehna is an accomplished researcher and educator in the field of Pharmaceutical Chemistry. He currently serves as an Associate Professor at the Faculty of Pharmacy, Kafrelsheikh University, Egypt. Eldehna’s academic journey began at Al-Azhar University, where he obtained his BSc in 2006 and MSc in 2011. He then pursued his PhD at Cairo University, completing it in 2015.

Eldehna’s research focuses on the intersection of chemistry and biology, with a particular emphasis on structure-based design and synthesis of novel small molecules for treating diseases such as cancer and infectious diseases. His work employs cutting-edge medicinal chemistry strategies to develop potential therapeutic agents.

Throughout his career, Eldehna has made significant contributions to the field, authoring or co-authoring over 250 publications in reputable international journals related to Pharmaceutical Sciences. He has extensive experience in editing and reviewing submissions, having handled approximately 100 edits and over 600 reviews. This experience, combined with his broad network of colleagues and collaborators, enables him to contribute significantly to the advancement of pharmaceutical research and publication. His expertise has been recognized globally, as evidenced by his inclusion in the Stanford University-Elsevier list of the TOP 2% of the world’s scientists in Medicinal and Biomolecular Chemistry for four consecutive years (2021-2024). Additionally, his contributions were further acknowledged when he received the State Encouragement Award in 2022.

Field of Interest:

• Drug Design and Development
• Medicinal Chemistry
• Pharmaceutical Organic Synthesis
• Bioorganic Chemistry
• Phytochemistry